Replies to post #25234 on RespireRx Pharmaceuticals Inc (RSPI)

[haysaw]

Thank you for participating Neuro. The problem I have with your parallels, is that we don't consider Ampakines in the same class, with the same potential, as these other companies. If the results of Cor's science are not giving them leverage in this dog eat dog world, than it is up to management to do it.

[asuhowe]

Neuro,
The thing that has perplexed me since joining this board has been your posivite support of management and continued opinion that COR has something incredibly unique and insanely ignored .. even with a .30 share price and the coffers running out... The reality of the situation just didn't add up.

Is it your opinion then that if the Nuclear Winter did not happen, and it was business as usual for the Pharma industry, that COR would have had a decent deal by now?

Is the hope at this point that COR is able to survive this anomoly period, and then reap the beneifts if it is able to survive and BPs swing to the other end of the pendulum?
What's your prognostication for COR going forward in light of all you have seen over th last 2 years, and the current state of the Pharma industry..

Cheers.

[Market_Fest4]

neuro,
I do not run a business with employees, and have only a rudimentary knowlege of chemistry. But I will tell you this much:

If I were the CEO of Cortex for the last six months, I would be busting my ass getting the ampakine story some traction. I would explore countless creative approaches tirelessly. And one or two would work. That's just who I am. Now, I don't like wearing suits and behaving like a corporate shmoe. But, who cares about that crap, as long as you produce results. Ex: Steve Jobs and his black turtlenecks.

I have the impression that management from Cortex, is management here because they used to be management somewhere else and they interview well enough. These guys seem to be plain vanilla, at best. Certainly not equipped to think outside of the box enough to do anything more than status quo. I'd love to eat crow in this, but we both know I'm right.

IF ampakines really do what the various POC trials claim, the right leader could turn this lead into gold. That's why I rip on management. So far, they have squandered some pretty cool IP. And nobody in the mainstream has ever heard of Cortex. What a waste.
MF4

[enemem]

The changed rules that cor has to adapt to is that the indication outlicencing model isn't going to work in the current buyer's market. Too few funds get raised to hopscotch from indication to indication.

My guess is that a big pharma would be interested in partnering for the whole low-impact platform because of the eventual off-prescription market for ampakines as cognitive enhancers, irrespective of the quite lucrative RD, ADHD indications.

I think that outlicencing the whole low-impact platform is a risky move, and the numbers may not justify it. I would prefer it to selling the company however, and just don't think there's enough inducement for the BPs to partner on an indication-by-indication outlicencing strategy. There are too many other companies competing for BP attention on that basis, and cor needs to separate itself from the pack.

My main point is that evidence suggests that BPs have little interest in the indication-based inlicencing approach. They'd rather just buy the companies with valuable IP. In the case of cor, the low-impacts are a substantial enough platform that a partnership rather than a buyout will remain an attractive option, particularly for a forward-thinking IP that recognizes the scientific talent at cor.